ArticleProbiotics and antimicrobial proteins2026
Superior Probiotic Potential of Saccharomyces cerevisiae YH14: In Vitro and In Vivo Evaluation for Animal Nutrition and Health.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Potent Probiotic YeastACS omega · 2026Article
- Yeast (Journal of advanced veterinary and animal research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The gastrointestinal tract of native animals represents a valuable reservoir of probiotic candidates. In this study, yeast strains were isolated from the feces of healthy native pigs raised in southern Thailand and evaluated for probiotic potential, safety, and extracellular enzyme production in vitro. The most promising isolate, Saccharomyces cerevisiae YH14, was selected for in vivo evaluation in a murine model. YH14 exhibited robust growth at 37 °C and demonstrated high tolerance to acidic (127.38%) and bile salt (139.94%) conditions. The strain showed strong auto-aggregation (90.09%), cell surface hydrophobicity (59.21%), and notable adhesion to Caco-2 cells (43.18%). Co-aggregation with enteric pathogens-including enterohemorrhagic E. coli (55.37%), enteropathogenic E. coli (57.91%), and Salmonella Typhimurium (56.62%)-was observed at intermediate levels. YH14 was nonhemolytic and produced beneficial feed enzymes, including xylanase and phytase. In vivo, administration of YH14 induced no mortality, behavioral changes, or adverse effects on feed intake and body weight gain. Histological examination revealed preserved tissue architecture in the intestine, liver, and spleen, with no signs of inflammation. Moreover, YH14 modulated the gut microbiota by promoting beneficial bacterial populations and suppressing potential pathogens, without significantly altering overall microbiome diversity. These findings support the potential application of S. cerevisiae YH14 as a probiotic feed additive for improving gut health and digestive efficiency in livestock.
Indexed as
Identifiers
40715751What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.